内镜逆行胰胆管造影术后胰腺炎的药物预防  

Drug prevention of post-ERCP pancreatitis

作　　者：王钧[1] 白飞虎[2] 周毅[1] 

机构地区：[1]解放军第451医院消化内科,陕西西安710054 [2]宁夏医科大学附属医院消化内科

出　　处：《胃肠病学和肝病学杂志》2011年第7期682-684,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：内镜逆行胰胆管造影术(endoscop ic retrograde cholangiopancreatography,ERCP)已发展成为肝胆胰疾病的重要诊治手段,ERCP术后胰腺炎(post-ERCP pancreatitis,PEP)是ERCP术后最常见、最严重的并发症之一,常导致住院日的延长,费用的增加,甚至危及患者的生命。本文对PEP的的定义、分级及药物预防方面的最新研究进展做一综述。Acute pancreatitis is one of most common major complication of endoscopic retrograde cholangiopancreatography（ERCP）,ERCP may result in prolonged hospitalisation,the need for further intervention.The recent advances in definition,classification,especially drug prevention of post-ERCP pancreatitis were reviewed in this paper.

关 键 词：内镜逆行胰胆管造影术 胰腺炎 药物预防 

分 类 号：R576[医药卫生—消化系统]